

FACULTY

DINO AMADORI	MELDOLA (I)
DIRK ARNOLD	FREIBURG (D)
CARLO BARONE	ROME (I)
GIORDANO D. BERETTA	BERGAMO (I)
GUIDO BIASCO	BOLOGNA (I)
LUIGI BOLONDI	BOLOGNA (I)
CORRADO BONI	REGGIO EMILIA (I)
ALBA BRANDES	BOLOGNA (I)
STEFANO CASCINU	ANCONA (I)
FORTUNATO CIARDIELLO	NAPLES (I)
BRUNO DANIELE	BENEVENTO (I)
FRANCESCO DI COSTANZO	FLORENCE (I)
ALFREDO FALCONE	PISA (I)
JESUS GARCIA FONCILLAS	MADRID (E)
ROBERTO LABIANCA	BERGAMO (I)
EVARISTO MAIELLO	S. GIOVANNI ROTONDO (I)
NICOLA NORMANNO	NAPLES (I)
ALICIA OKINES	LONDON (UK)
CARMINE PINTO	BOLOGNA (I)
HANS JOACHIM SCHMOLL	HALLE (D)
SALVATORE SIENA	MILAN (I)
GIAMPAOLO TORTORA	VERONA (I)
ALBERTO ZANIBONI	BRESCIA (I)

UNRESTRICTED GRANT BY
gold


Answers That Matter.


We Innovate Healthcare

silver

 Bayer HealthCare


SANOFI

Scientific coordination: Oncologia Medica

Policlinico S. Orsola- Malpighi | Bologna

Venue

Policlinico S. Orsola Malpighi
Aula Murri | Padiglione 27

Via Pietro Albertoni 15 | 40138 Bologna

Per raggiungere la sede si consiglia l'accesso di viale Ercolani,
dopo la sbarra entrare nella prima palazzina sita sulla sinistra

Organizing secretariat & provider



Viale Carducci 50 | 40125 Bologna
tel. 051.220427 | fax 051.0822077
info@mitcongressi.it
www.mitcongressi.it


ECM: sono stati richiesti crediti per Oncologi, Biologi, Chirurghi,
Radioterapisti, Anatomopatologi, Gastroenterologi.

ISCRIZIONE: l'iscrizione è gratuita previa registrazione online
eseguibile accedendo al sito www.mitcongressi.it sezione
"Recent advances in anti-angiogenic therapy
in gastro-intestinal cancer"



RECENT ADVANCES IN ANTI-ANGIOGENIC THERAPY IN GASTRO-INTESTINAL CANCER

President: Carmine Pinto



Bologna September 18, 2013
Policlinico S. Orsola | Aula Murri

**RECENT ADVANCES
IN ANTI-ANGIOGENIC THERAPY
IN GASTRO-INTESTINAL
CANCER**

Bologna September 18, 2013
Policlinico S. Orsola | Aula Murri

9:00
Registration

9:30
Introduction
Carmine Pinto

**Session I
Biological mechanisms and angiogenic inhibitors**

Chairs: Dino Amadori, Roberto Labianca

9:40
Angiogenesis and anti-angiogenesis in gastro-intestinal cancer
Giampaolo Tortora

10:00
Predictive biomarkers and resistance to VEGF-targeted therapies
Jesus Garcia Foncillas

10:20
Clinical evaluation: is RECIST still relevant in the era of anti-angiogenic drugs ?
Alberto Zaniboni

Discussion

10:50
Coffee Break

**Session II
Anti-angiogenic therapy in gastric cancer**

Chairs: Alba Brandes, Evaristo Maniello

11:10
Anti-angiogenic therapy in peri-operative treatment
Alicia Okines

11:30
Bevacizumab in metastatic disease
Francesco Di Costanzo

11:50
Ramucirumab in metastatic disease
Carlo Barone

12:10
Lecture
Update in pancreatic cancer
Stefano Cascinu

Discussion

**Session III
Anti-angiogenic therapy in hepatocellular carcinoma**
Chairs: Giordano D. Beretta, Guido Biasco

12:40
Anti-angiogenic activity in the treatment of hepatocellular carcinoma
Luigi Bolondi

13:00
New anti-angiogenic therapies
Bruno Daniele

Discussion

13:30
Lunch
**Session IV
Anti-angiogenic therapy in colorectal cancer**
Chairs: Corrado Boni, Salvatore Siena

14:30
Bevacizumab: when and how long ?
Dirk Arnold

14:50
Aflibercept: when and how long ?
Hans-Joachim Schmoll

15:10
Present and future of regorafenib
Fortunato Ciardiello

15:30
Optimal sequence of the anti-angiogenic drugs
Alfredo Falcone

15:50
Anti-angiogenic or anti-EGFR therapy in first line: which rational ?
Nicola Normanno

Discussion

16:30
Conclusion
Carmine Pinto

